BeiGene, Ltd., forthcomingly known as
BeOne Medicines, has made some noteworthy strides in the biotech market. The company has outperformed analyst forecasts and was recently recommended as a 'buy' by Morgan Stanley. It has relocated its global base to Switzerland and successfully rebranded to BeOne Medicines, also, which is expected to adopt new names from June 30. BeiGene has also executed a royalty deal worth upwards of $950 million with
Royalty Pharma for Amgen's lung cancer drug. BeiGene recently received a positive CHMP opinion and FDA approval for
TEVIMBRA® used as a first-line treatment for nasopharyngeal cancer. Even though its stock price skyrocketed, BeiGene's price and business performance are still lagging within the industry. The company has returned robust revenue growth and revenues surpassed expectations in its full year, 2024. BeiGene's new drugs, such as ociperlimab, have shown positive results.
However, USPTO invalidated a patent from Pharmacyclics that was claimed against BeiGene guaranteeing its market position. Moreover, collaborations are underway with other companies like nference and ImmunityBio to push for new research and trials in B-cell cancer and non-small cell lung cancer, respectively. Despite going through a rough patch with a recent 15% pullback, the combination of product innovation, regulatory wins, strategic collaborations, and financial performance has strengthened BeiGene's market position.
BeiGene, Ltd. News Analytics from Mon, 20 Dec 2021 08:00:00 GMT to Thu, 04 Dec 2025 09:12:29 GMT -
Rating 7
- Innovation 5
- Rumor -3
